Physician profile
Kyle G Carpenter
NPI 1962713081
$2,774.82
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $967 · 2021: $17.12 · 2022: $70.16 · 2024: $28.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $266.67 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $253.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $219.12 | 2019-2020 | |
| Emd Serono, INC. | $206.70 | 2019-2020 | |
| Genzyme Corporation | $193.40 | 2019-2020 | |
| Allergan, INC. | $187.30 | 2019-2020 | |
| Ucb, INC. | $139.13 | 2019-2020 | |
| Acorda Therapeutics, INC | $134.58 | 2019 | |
| Alexion Pharmaceuticals, INC. | $130.54 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $114.11 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $74.68 | 2019-2020 | |
| Abbvie INC. | $74.49 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $64.12 | 2019-2020 | |
| Csl Behring | $64.02 | 2020 | |
| Acadia Pharmaceuticals INC | $56.46 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $55.13 | 2020 | |
| Lundbeck LLC | $54.94 | 2019-2020 | |
| Eisai INC. | $54.93 | 2020 | |
| Amgen INC. | $54.79 | 2019-2020 | |
| Boston Scientific Corporation | $47.98 | 2019 | |
| Ge Healthcare | $35.33 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.59 | 2022 | |
| Neurocrine Biosciences, INC. | $28.90 | 2020 | |
| Hospira, INC. | $28.20 | 2024 | |
| Janssen Pharmaceuticals, INC | $27.07 | 2022 | |
| Lilly USA, LLC | $24.54 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $22.66 | 2019 | |
| Livanova USA, INC. | $20.53 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.07 | 2019 | |
| Harmony Biosciences LLC | $15.12 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $14.12 | 2019 | |
| Aquestive Therapeutics, INC. | $13.68 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.41 | 2019 | |
| Zyla Life Sciences, INC. | $13.24 | 2019 | |
| Mallinckrodt Hospital Products INC. | $12.65 | 2020 | |
| Mdd US Operations, LLC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.